Latest Prana Biotechnology Ltd (PRAN) Headlines
Post# of 17
Posted On: 03/13/2014 1:21:27 AM
Latest Prana Biotechnology Ltd (PRAN) Headlines
Huntington's Reviewed by NeuroPerspective
PR Newswire - Tue Mar 04, 7:30AM CST
NI Research has released the March issue of NeuroPerspective, which reviews and assesses the range of neurotherapeutics programs in development for Huntington's Disease. Huntington's is a devastating orphan neurodegenerative disorder known to affect approximately 30,000 patients in the United States, with another 150-200,000 individuals genetically at risk for the disease. Recent weeks have seen the release of Phase II trial results in HD from both Prana Biotechnology and Raptor Pharmaceuticals, those results catalyzing fresh interest in this area.
A Busy Calendar of March Biotech Events
at The Street - Mon Mar 03, 12:13PM CST
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 01, 6:31AM CST
Sure, it's still cold across most of the country. After all, the famous groundhog in Punxsutawney, Pa., did see his shadow in early February. According to the legend, that means we still have a few more weeks of winter. However, some health-care...
Piston OpenStack 3.0: The Last OpenStack(R) Product You'll Ever Try
Marketwire - Tue Feb 25, 7:05AM CST
Piston Cloud Computing, Inc., the enterprise OpenStack(R) company, today announced, in conjunction with an Intelemage customer announcement, a new release of Piston OpenStack(TM), a turn-key software product that uses advanced systems intelligence to orchestrate an entire private cloud environment using commodity hardware.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biotech Stock 'Hate' Mailbag: Readers Riot Over Galena, Prana
at The Street - Thu Feb 20, 9:56AM CST
I've received so much hate email and tweets over the past week, enough to fill a special edition of the Mailbag.
Independent Experts Cast Doubt on Prana HD Drug Efficacy Claims
at The Street - Thu Feb 20, 7:25AM CST
Read what doctors not involved in Prana's PBT2 study had to say about the results announced Tuesday.
Why Prana Biotechnology Limited and Medbox Inc. Lost Big Today
David Williamson, The Motley Fool - Motley Fool - Wed Feb 19, 5:32PM CST
Prana Biotechnology Limited and Medbox Inc. were the big losers in the health-care space today, and in this segment from Wednesday's Market Checkup , Motley Fool health-care analyst David Williamson looks at what caused these two market...
New Huntington Disease Drug Is Safe, but Is It Effective?
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 19, 5:30PM CST
Prana Biotechnology 's Huntington disease drug, PBT2, is safe, but whether it helps patients enough to get approved remains to be seen. The press release headline "Prana Announces Successful Phase 2 Results in Huntington Disease Trial" sounds...
Company news for February 19, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 9:06AM CST
Companies in the News are: DUK,RAD,PRAN,AMWD
Prana Biotechnology Rises 39.31% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Feb 18, 5:19PM CST
Prana Biotechnology (NASDAQ
RAN) traded in a range yesterday that spanned from a low of $7.80 to a high of $10.74. Yesterday, the shares gained 39.3%, which took the trading range above the 3-day high of $8.78 on volume of 25.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Prana Biotechnology, Forest Laboratories, and United Fire Group Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 18, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Despite weaker than expected economic data, the broad-based ...
Cheerleading Tweets From Prana's Harvard Scientist Propel Shares Higher
at The Street - Tue Feb 18, 12:53PM CST
In which I engage in a Twitter spat with a Harvard professor about Prana Bio's Huntington disease drug.
Today’s Top Biotech Stories: Prana, Actavis, Forest Labs, and Novartis
Leo Sun, The Motley Fool - Motley Fool - Tue Feb 18, 7:56AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a...
Prana Bio Huntington's Disease Drug Fails Key Efficacy Hurdles
at The Street - Tue Feb 18, 5:51AM CST
As expected, Prana focused on positive safety results from its Huntington's study of PB2, but the drug didn't improve cognition and motor function enough to matter.
Prana Meets Primary Endpoint in Phase 2 REACH2HD Clinical Study of PBT2 for Treating Huntington Disease
PR Newswire - Tue Feb 18, 5:02AM CST
Key Points:
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 15, 8:00AM CST
While yet another winter storm system swept across much of the U.S. this week, the weather wasn't the only thing downright chilly. Several health-care stocks that had been on hot streaks took some deep plunges into icy waters over the past few days. ...
Ask a Fool: What's Your Foolish Take on Prana Biotechnology?
David Williamson, The Motley Fool - Motley Fool - Mon Feb 10, 8:31PM CST
In this video as part of The Motley Fool's "Ask a Fool" series, Fool health-care analyst David Williamson takes a question from a Fool reader, who asks, "What's your Foolish take on Prana Biotech ?" While there is a huge amount of investor...
Enanta Pharmaceuticals, Inc., ImmunoGen, Inc. and Prana Biotechnology Ltd Could Be Big Movers in Hea
George Budwell, The Motley Fool - Motley Fool - Fri Jan 31, 8:17AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a look at...
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 30, 3:21PM CST
The broad-based S&P 500 may have closed at its lowest level in more than two months yesterday on word that the Federal Open Market Committee was reducing its monthly bond-buying stimulus by $10 billion for a second straight month, but 41% of...
Huntington's Reviewed by NeuroPerspective
PR Newswire - Tue Mar 04, 7:30AM CST
NI Research has released the March issue of NeuroPerspective, which reviews and assesses the range of neurotherapeutics programs in development for Huntington's Disease. Huntington's is a devastating orphan neurodegenerative disorder known to affect approximately 30,000 patients in the United States, with another 150-200,000 individuals genetically at risk for the disease. Recent weeks have seen the release of Phase II trial results in HD from both Prana Biotechnology and Raptor Pharmaceuticals, those results catalyzing fresh interest in this area.
A Busy Calendar of March Biotech Events
at The Street - Mon Mar 03, 12:13PM CST
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 01, 6:31AM CST
Sure, it's still cold across most of the country. After all, the famous groundhog in Punxsutawney, Pa., did see his shadow in early February. According to the legend, that means we still have a few more weeks of winter. However, some health-care...
Piston OpenStack 3.0: The Last OpenStack(R) Product You'll Ever Try
Marketwire - Tue Feb 25, 7:05AM CST
Piston Cloud Computing, Inc., the enterprise OpenStack(R) company, today announced, in conjunction with an Intelemage customer announcement, a new release of Piston OpenStack(TM), a turn-key software product that uses advanced systems intelligence to orchestrate an entire private cloud environment using commodity hardware.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biotech Stock 'Hate' Mailbag: Readers Riot Over Galena, Prana
at The Street - Thu Feb 20, 9:56AM CST
I've received so much hate email and tweets over the past week, enough to fill a special edition of the Mailbag.
Independent Experts Cast Doubt on Prana HD Drug Efficacy Claims
at The Street - Thu Feb 20, 7:25AM CST
Read what doctors not involved in Prana's PBT2 study had to say about the results announced Tuesday.
Why Prana Biotechnology Limited and Medbox Inc. Lost Big Today
David Williamson, The Motley Fool - Motley Fool - Wed Feb 19, 5:32PM CST
Prana Biotechnology Limited and Medbox Inc. were the big losers in the health-care space today, and in this segment from Wednesday's Market Checkup , Motley Fool health-care analyst David Williamson looks at what caused these two market...
New Huntington Disease Drug Is Safe, but Is It Effective?
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 19, 5:30PM CST
Prana Biotechnology 's Huntington disease drug, PBT2, is safe, but whether it helps patients enough to get approved remains to be seen. The press release headline "Prana Announces Successful Phase 2 Results in Huntington Disease Trial" sounds...
Company news for February 19, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 9:06AM CST
Companies in the News are: DUK,RAD,PRAN,AMWD
Prana Biotechnology Rises 39.31% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Feb 18, 5:19PM CST
Prana Biotechnology (NASDAQ
RAN) traded in a range yesterday that spanned from a low of $7.80 to a high of $10.74. Yesterday, the shares gained 39.3%, which took the trading range above the 3-day high of $8.78 on volume of 25.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. Why Prana Biotechnology, Forest Laboratories, and United Fire Group Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 18, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Despite weaker than expected economic data, the broad-based ...
Cheerleading Tweets From Prana's Harvard Scientist Propel Shares Higher
at The Street - Tue Feb 18, 12:53PM CST
In which I engage in a Twitter spat with a Harvard professor about Prana Bio's Huntington disease drug.
Today’s Top Biotech Stories: Prana, Actavis, Forest Labs, and Novartis
Leo Sun, The Motley Fool - Motley Fool - Tue Feb 18, 7:56AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a...
Prana Bio Huntington's Disease Drug Fails Key Efficacy Hurdles
at The Street - Tue Feb 18, 5:51AM CST
As expected, Prana focused on positive safety results from its Huntington's study of PB2, but the drug didn't improve cognition and motor function enough to matter.
Prana Meets Primary Endpoint in Phase 2 REACH2HD Clinical Study of PBT2 for Treating Huntington Disease
PR Newswire - Tue Feb 18, 5:02AM CST
Key Points:
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 15, 8:00AM CST
While yet another winter storm system swept across much of the U.S. this week, the weather wasn't the only thing downright chilly. Several health-care stocks that had been on hot streaks took some deep plunges into icy waters over the past few days. ...
Ask a Fool: What's Your Foolish Take on Prana Biotechnology?
David Williamson, The Motley Fool - Motley Fool - Mon Feb 10, 8:31PM CST
In this video as part of The Motley Fool's "Ask a Fool" series, Fool health-care analyst David Williamson takes a question from a Fool reader, who asks, "What's your Foolish take on Prana Biotech ?" While there is a huge amount of investor...
Enanta Pharmaceuticals, Inc., ImmunoGen, Inc. and Prana Biotechnology Ltd Could Be Big Movers in Hea
George Budwell, The Motley Fool - Motley Fool - Fri Jan 31, 8:17AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a look at...
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 30, 3:21PM CST
The broad-based S&P 500 may have closed at its lowest level in more than two months yesterday on word that the Federal Open Market Committee was reducing its monthly bond-buying stimulus by $10 billion for a second straight month, but 41% of...
(0)
(0)Alterity Therapeutics Limited (ATHE) Stock Research Links
Scroll down for more posts ▼